BeiGene, Ltd. (Form: 3, Received: 02/02/2016 19:37:15)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*
BAKER BROS. ADVISORS LP
2. Date of Event Requiring Statement (MM/DD/YYYY) 2/2/2016
3. Issuer Name and Ticker or Trading Symbol
BeiGene, Ltd. [BGNE]

(Last)        (First)        (Middle)
667 MADISON AVENUE, 21ST FLOOR
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)
NEW YORK, NY 10065

(City)              (State)              (Zip) 5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4) 2. Amount of Securities Beneficially Owned
(Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security
(Instr. 4) 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Date Exercisable Expiration Date Title Amount or Number of Shares

Series A Preferred shares ⁽¹⁾ ⁽¹⁾ Ordinary shares 4382118 ⁽¹⁾ I See Footnote ⁽²⁾ ⁽⁸⁾

Series A Preferred shares ⁽¹⁾ ⁽¹⁾ Ordinary shares 44572171 ⁽¹⁾ I See Footnote ⁽³⁾ ⁽⁸⁾

Series A Preferred shares ⁽¹⁾ ⁽¹⁾ Ordinary shares 582747 ⁽¹⁾ I See Footnote ⁽⁴⁾ ⁽⁸⁾

Series A-2 Preferred shares ⁽⁵⁾ ⁽⁵⁾ Ordinary shares 1912167 ⁽⁵⁾ I See Footnote ⁽⁶⁾ ⁽⁸⁾

Series A-2 Preferred shares ⁽⁵⁾ ⁽⁵⁾ Ordinary shares 26292961 ⁽⁵⁾ I See Footnote ⁽⁷⁾ ⁽⁸⁾

Ordinary stock warrant (right to buy) 8/12/2014 8/12/2019 ⁽⁹⁾ Ordinary shares 238850 $0.675 I See Footnote ⁽¹⁰⁾ ⁽⁸⁾

Ordinary stock warrant (right to buy) 8/12/2014 8/12/2019 ⁽⁹⁾ Ordinary shares 2296890 $0.675 I See Footnote ⁽¹¹⁾ ⁽⁸⁾

Ordinary stock warrant (right to buy) 8/12/2014 8/12/2019 ⁽⁹⁾ Ordinary shares 56853 $0.675 I See Footnote ⁽¹²⁾ ⁽⁸⁾

Explanation of Responses:

(1) These securities consist of Series A Preferred Shares (the "Series A Shares") of BeiGene, Ltd. (the "Issuer"), which are convertible at any time into the Issuer's Ordinary Shares on a 1-to1 basis and will automatically convert into Common Stock of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. The Series A Shares do not have an expiration date.

(2) As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,382,118 Series A Shares held directly by 667,L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

(3) As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 44,572,171 Series A Shares held directly by Baker Brothers Life Sciences, L.P. ("Life Sciences"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

(4) As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 582,747 Series A Shares held directly by 14159,L.P. ("14159", and together with 667 and Life Sciences, the "Funds"), a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

(5) These securities consist of Series A-2 Preferred Shares ("Series A-2 Shares") of the Issuer, which are convertible at any time into the Issuer's Ordinary Shares on a 1-to-1 basis and will automatically convert into Common Stock of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. The Series A-2 Shares do not have an expiration date.

(6) As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 1,912,167 Series A-2 Shares held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

(7) As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 26,292,961 Series A-2 Shares held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

(8) Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

(9) Expires at the earlier of August 12, 2019, sale of the Issuer or upon the closing of a Qualified IPO (as defined in the ordinary stock warrants) by the Issuer.

(10) As a result of their interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. baker may be deemed to have an indirect pecuniary interest in the 238,850 ordinary shares of the Issuer underlying ordinary stock warrants ("Warrants") directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

(11) As a result of their interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. baker may be deemed to have an indirect pecuniary interest in the 2,296,890 ordinary shares of the Issuer underlying Warrants directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

(12) As a result of their interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. baker may be deemed to have an indirect pecuniary interest in the 56,853 ordinary shares of the Issuer underlying Warrants directly held by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

Remarks:
Michael Goller and Ranjeev Krishana, employees of Baker Bros. Advisors LP, are directors of BeiGene, Ltd. (the "Issuer"). By virtue of their representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BAKER BROS. ADVISORS LP
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY 10065 X X

BAKER JULIAN
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY 10065 X X

BAKER FELIX
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY 10065 X X

Baker Bros. Advisors (GP) LLC
667 MADISION AVENUE 21ST FLOOR
NEW YORK, NY 10065 X X

Baker Brothers Life Sciences LP
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY 10065 X X

667, L.P.
667 MADISON AVENUE 21ST FLOOR
NEW YORK, NY 10065 X X

14159, L.P.
667 MADISION AVENUE, 21ST FLOOR
NEW YORK, NY 10065 X X

Signatures

Name: Scott L. Lessing Title:President /s/ Scott L. Lessing 2/2/2016

^** Signature of Reporting Person Date

/s/ Julian C. Baker 2/2/2016

^** Signature of Reporting Person Date

/s/ Felix J. Baker 2/2/2016

^** Signature of Reporting Person Date

Name: Scott L. Lessing Title: President /s/ Scott L. Lessing 2/2/2016

^** Signature of Reporting Person Date

Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker 2/2/2016

^** Signature of Reporting Person Date

Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P Name: Scott L. Lessing, Title: President /s/ Scott L. 2/2/2016

^** Signature of Reporting Person Date

Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 14159, L.P., pursuant to authority granted by 14159 Capital, L.P., GP to 14159, L.P Name:Scott L. Lessing, Title: President /s/ Scott L. 2/2/2016

^** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Preferred shares	⁽¹⁾	⁽¹⁾	Ordinary shares	4382118	⁽¹⁾	I	See Footnote ⁽²⁾ ⁽⁸⁾
Series A Preferred shares	⁽¹⁾	⁽¹⁾	Ordinary shares	44572171	⁽¹⁾	I	See Footnote ⁽³⁾ ⁽⁸⁾
Series A Preferred shares	⁽¹⁾	⁽¹⁾	Ordinary shares	582747	⁽¹⁾	I	See Footnote ⁽⁴⁾ ⁽⁸⁾
Series A-2 Preferred shares	⁽⁵⁾	⁽⁵⁾	Ordinary shares	1912167	⁽⁵⁾	I	See Footnote ⁽⁶⁾ ⁽⁸⁾
Series A-2 Preferred shares	⁽⁵⁾	⁽⁵⁾	Ordinary shares	26292961	⁽⁵⁾	I	See Footnote ⁽⁷⁾ ⁽⁸⁾
Ordinary stock warrant (right to buy)	8/12/2014	8/12/2019 ⁽⁹⁾	Ordinary shares	238850	$0.675	I	See Footnote ⁽¹⁰⁾ ⁽⁸⁾
Ordinary stock warrant (right to buy)	8/12/2014	8/12/2019 ⁽⁹⁾	Ordinary shares	2296890	$0.675	I	See Footnote ⁽¹¹⁾ ⁽⁸⁾
Ordinary stock warrant (right to buy)	8/12/2014	8/12/2019 ⁽⁹⁾	Ordinary shares	56853	$0.675	I	See Footnote ⁽¹²⁾ ⁽⁸⁾

Explanation of Responses:
(1)	These securities consist of Series A Preferred Shares (the "Series A Shares") of BeiGene, Ltd. (the "Issuer"), which are convertible at any time into the Issuer's Ordinary Shares on a 1-to1 basis and will automatically convert into Common Stock of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. The Series A Shares do not have an expiration date.
(2)	As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,382,118 Series A Shares held directly by 667,L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
(3)	As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 44,572,171 Series A Shares held directly by Baker Brothers Life Sciences, L.P. ("Life Sciences"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
(4)	As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 582,747 Series A Shares held directly by 14159,L.P. ("14159", and together with 667 and Life Sciences, the "Funds"), a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.
(5)	These securities consist of Series A-2 Preferred Shares ("Series A-2 Shares") of the Issuer, which are convertible at any time into the Issuer's Ordinary Shares on a 1-to-1 basis and will automatically convert into Common Stock of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. The Series A-2 Shares do not have an expiration date.
(6)	As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 1,912,167 Series A-2 Shares held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
(7)	As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 26,292,961 Series A-2 Shares held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
(8)	Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
(9)	Expires at the earlier of August 12, 2019, sale of the Issuer or upon the closing of a Qualified IPO (as defined in the ordinary stock warrants) by the Issuer.
(10)	As a result of their interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. baker may be deemed to have an indirect pecuniary interest in the 238,850 ordinary shares of the Issuer underlying ordinary stock warrants ("Warrants") directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
(11)	As a result of their interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. baker may be deemed to have an indirect pecuniary interest in the 2,296,890 ordinary shares of the Issuer underlying Warrants directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
(12)	As a result of their interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. baker may be deemed to have an indirect pecuniary interest in the 56,853 ordinary shares of the Issuer underlying Warrants directly held by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
BAKER FELIX 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE 21ST FLOOR NEW YORK, NY 10065	X	X
Baker Brothers Life Sciences LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X
667, L.P. 667 MADISON AVENUE 21ST FLOOR NEW YORK, NY 10065	X	X
14159, L.P. 667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY 10065	X	X

Signatures
Name: Scott L. Lessing Title:President /s/ Scott L. Lessing		2/2/2016
^** Signature of Reporting Person		Date
/s/ Julian C. Baker		2/2/2016
^** Signature of Reporting Person		Date
/s/ Felix J. Baker		2/2/2016
^** Signature of Reporting Person		Date
Name: Scott L. Lessing Title: President /s/ Scott L. Lessing		2/2/2016
^** Signature of Reporting Person		Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker		2/2/2016
^** Signature of Reporting Person		Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P Name: Scott L. Lessing, Title: President /s/ Scott L.		2/2/2016
^** Signature of Reporting Person		Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 14159, L.P., pursuant to authority granted by 14159 Capital, L.P., GP to 14159, L.P Name:Scott L. Lessing, Title: President /s/ Scott L.		2/2/2016
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.